Lymphoma & Plasma Cell Disorders
Feature
2017 notches up some landmark approvals
News
Group calls on WHO to help fight HTLV-1
A group of scientists and activists are calling on the World Health Organization (WHO) to fight the spread of human T-cell leukemia virus subtype...
From the Journals
5-year data show deepening response with ibrutinib in CLL
The long-term findings don’t raise red flags about safety with the drug in CLL.
News
Team identifies new prognostic factor for MF
New research suggests DNA sequencing can reveal which patients with early stage mycosis fungoides (MF) will develop aggressive disease. By...
News
‘Long-term benefits’ with nivolumab in cHL
Nivolumab can provide “long-term benefits” in patients with relapsed or refractory classical Hodgkin lymphoma (cHL), according to researchers....
Conference Coverage
Novel targeted cancer drugs cause fewer arrhythmias
Tyrosine kinase inhibitors and other targeted agents have 40% lower cardiac arrhythmia risk than anthracycline-based regimens.
News
FDA approves anti-CD38 with VMP in myeloma
The FDA approved the drug in combination with VMP for patients who are ineligible for transplant.
News
Drug granted fast track designations for FL, DLBCL
The US Food and Drug Administration (FDA) has granted 2 fast track designations to 5F9, an anti-CD47 antibody. The designations are for 5F9 as a...
Conference Coverage
Early results favor combo IL-15/anti-CD20 in indolent NHL
CHICAGO – The researchers tested the combination of rituximab with the IL-15 receptor super agonist complex ALT-803.
News
Novartis CAR T-cell therapy adds a lymphoma indication
The new approval puts tisagenlecleucel head to head with Gilead’s axicabtagene ciloleucel.
News
FDA issues CRL for proposed biosimilar rituximab
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed...